Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

Inclusion Criteria: * Written Informed Consent to participate in the study * Willingness to actively participate in the study and to come to the scheduled visits * Female and/or male * From 18 to 65 years of age * Uniform skin color and no erythema or dark pigmentation in the test area * ITA° \> 28 in the test area Exclusion Criteria: * Female subjects: Pregnancy or lactation * Drug addicts, alcoholics * AIDS, HIV-positive or infectious hepatitis * Conditions which exclude a participation or might influence the test reaction/evaluation * Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area * One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases * Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years * Insulin-dependent diabetes mellitus * Electronic implant (e.g. pace maker, insulin pump, hearing aid, and the like) that cannot be removed during irradiation * Documented allergies to cosmetic products and/or ingredients * Active skin disease at the test area * Irregularly tanned skin in the test area * Medical history of dysplastic nevi, melanoma or other skin carcinoma * Medical history of abnormal response to sunlight * Regular use of tanning beds (more than 10 times within the last 6 months) * Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation * Usage of medication with known photo-toxic and/or photo-sensitizing potential (e.g. some antibiotics, blood pressure regulating agents and antidepressants agents; hypericum perforatum) within the last 14 days prior to the start of the study and/or throughout the entire course of the study * Any topical medication at the test area within the last 7 days prior to the start of the study and/or throughout the entire course of the study * Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study and/or throughout the entire course of the study * Systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study and/or throughout the entire course of the study